Skye Bioscience Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Skye Bioscience's earnings have been declining at an average annual rate of -53.2%, while the Biotechs industry saw earnings growing at 19% annually.
Belangrijke informatie
-53.2%
Groei van de winst
-5.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | n/a |
Rendement op eigen vermogen | -58.1% |
Nettomarge | n/a |
Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Skye Bioscience geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -42 | 13 | 9 |
31 Mar 24 | 0 | -37 | 10 | 7 |
31 Dec 23 | 0 | -38 | 8 | 6 |
30 Sep 23 | 0 | -43 | 13 | 6 |
30 Jun 23 | 0 | -21 | 12 | 6 |
31 Mar 23 | 0 | -22 | 13 | 6 |
31 Dec 22 | 0 | -19 | 12 | 6 |
30 Sep 22 | 0 | -12 | 6 | 6 |
30 Jun 22 | 0 | -11 | 6 | 4 |
31 Mar 22 | 0 | -9 | 5 | 4 |
31 Dec 21 | 0 | -9 | 5 | 3 |
30 Sep 21 | 0 | -8 | 5 | 2 |
30 Jun 21 | 0 | -7 | 4 | 2 |
31 Mar 21 | 0 | -6 | 4 | 2 |
31 Dec 20 | 0 | -7 | 4 | 2 |
30 Sep 20 | 0 | 0 | 5 | 2 |
30 Jun 20 | 0 | -4 | 4 | 2 |
31 Mar 20 | 0 | 13 | 5 | 3 |
31 Dec 19 | 0 | 1 | 4 | 2 |
30 Sep 19 | 0 | -10 | 4 | 2 |
30 Jun 19 | 0 | -7 | 4 | 1 |
31 Mar 19 | 0 | -26 | 4 | 1 |
31 Dec 18 | 0 | -19 | 4 | 0 |
30 Sep 18 | 0 | -14 | 4 | 0 |
30 Jun 18 | 0 | -12 | 4 | 0 |
31 Mar 18 | 0 | -10 | 4 | 0 |
31 Dec 17 | 0 | -4 | 4 | 0 |
30 Sep 17 | 0 | -5 | 4 | 0 |
30 Jun 17 | 0 | -5 | 4 | 0 |
31 Mar 17 | 0 | -4 | 4 | 1 |
31 Dec 16 | 0 | -4 | 4 | 1 |
30 Sep 16 | 0 | -3 | 4 | 1 |
30 Jun 16 | 0 | -3 | 4 | 1 |
31 Mar 16 | 0 | -6 | 4 | 0 |
31 Dec 15 | 0 | -5 | 4 | 0 |
30 Sep 15 | 0 | -6 | 5 | 0 |
30 Jun 15 | 0 | -6 | 5 | 0 |
31 Mar 15 | 0 | -4 | 3 | 0 |
31 Dec 14 | 0 | -3 | 3 | 0 |
30 Sep 14 | 0 | -1 | 1 | 0 |
30 Jun 14 | 0 | 0 | 0 | 0 |
31 Mar 14 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: SKYE is currently unprofitable.
Groeiende winstmarge: SKYE is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SKYE is unprofitable, and losses have increased over the past 5 years at a rate of 53.2% per year.
Versnelling van de groei: Unable to compare SKYE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SKYE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: SKYE has a negative Return on Equity (-58.08%), as it is currently unprofitable.